US2259492A - Therapeutic preparation of bismuth and method of preparing same - Google Patents
Therapeutic preparation of bismuth and method of preparing same Download PDFInfo
- Publication number
- US2259492A US2259492A US210772A US21077238A US2259492A US 2259492 A US2259492 A US 2259492A US 210772 A US210772 A US 210772A US 21077238 A US21077238 A US 21077238A US 2259492 A US2259492 A US 2259492A
- Authority
- US
- United States
- Prior art keywords
- bismuth
- arsenic
- acid
- solution
- antimony
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229910052797 bismuth Inorganic materials 0.000 title description 22
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 title description 22
- 238000002360 preparation method Methods 0.000 title description 14
- 238000000034 method Methods 0.000 title description 7
- 230000001225 therapeutic effect Effects 0.000 title description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 19
- 229910052785 arsenic Inorganic materials 0.000 description 17
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 15
- 229910052787 antimony Inorganic materials 0.000 description 13
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 13
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000002739 metals Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 208000006379 syphilis Diseases 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 150000001622 bismuth compounds Chemical class 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100001231 less toxic Toxicity 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 201000002311 trypanosomiasis Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 150000001621 bismuth Chemical class 0.000 description 2
- -1 cevitamic acid compound Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 208000008316 Arsenic Poisoning Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002084 anti-luetic effect Effects 0.000 description 1
- OEYOHULQRFXULB-UHFFFAOYSA-N arsenic trichloride Chemical compound Cl[As](Cl)Cl OEYOHULQRFXULB-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079905 intestinal adsorbents bismuth preparations Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 229910052752 metalloid Inorganic materials 0.000 description 1
- 150000002738 metalloids Chemical class 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001742 trypanosomicidal effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/94—Bismuth compounds
Definitions
- the present invention relates to therapeutic preparations for the administration of bismuth, antimony and arsenic into the human organism.
- antimony and arsenic are now in use for the treatment of various diseases, such as syphilis and trypanosomiasis, but their application is frequently attended by irritation and even poisoning, and sometimes gives rise to dermatitis, gingivitis and other affections. While these detrimental side eifects are generally due to the susceptibility oi the patient to bismuth, antimony and arsenic poisoning, they are frequently due,
- the bismuth, antimony and arsenic are administered in the form of the cevitamate or laevo-ascorbate in dosages common for these metals.
- the cevitamic acid radical oiiers an unusually effective and non-toxic vehicle for the introduction of these otherwise poisonous metals or metalloids into the human organism.
- the peculiar structure 01' cevitamic acid which supplies both oxidation and reduction mechanisms. makes it a remarkable detoxicating agent and the bismuth, antimony and arsenic cevitamates are thus less toxic and more easily tolerated by the body than known preparations of bismuth, antimony and arsenic.
- cevitamic acid compound of the above named metals are quite soluble in water and with the aid of a stabilizing agent, and particularly at a pH value of about 7.6 or slightly higher, can be kept indefinitely in solution.
- these salts possess also the physiological action of cevitamic acid, and thus simultaneously act to correct morbid conditions arising from a deficiency of vitamin C.
- aiiltercellandtotheilltrate25caliu50asolution (containing 250 mg.) were now'added to stabilize it and it was brought down to a pH around 7.6 with excess cevitamic acid. It was then made up to 150 cc. with distilled water and bottled immediately. The preparation should contain approximately 20 mg. Bi per cc.
- the reaction may be represented as follows:
- the solutions of the cevitamates above described may be packaged in ampoules or ii desired m the solid condition in the form of tablets.
- e compounds may be prepared in an indifierent atmosphere, like ,Nz or CO2, but this is not absolutely necessary; while if desired the ampoules may be charged in such an atmosphere or may have C02 dissolved in the solution.
- an indifierent atmosphere like ,Nz or CO2
- Various organic acids can be employed for adjusting the pH to a lower alkalinity, care being taken to avoid precipitation. Tartaric, citric, gluconic and other 'injectible organic acids may be used for this purpose. To bring the pH down from above 9 to 8, tartaric or citric acid is satisfactory, whereas gluconic acid may cause precipitation.
- Local anaesthetics such as chlorbutanol or benzyl alcohol may be added to reduce tissue sensitivity. They likewise have a desirable eiiect on the stability of the solution.
- the bismuth, antimony and arsenic cevitamates are administered parenterally, preferably intramuscularly.
- the dosage may amount to 20 to 40 mg. of the metal once or twice weekly. They are all suitable for the treatment 01! syphilis and protozoan diseases, like trypanosomiasis.
- a salt of cevitamic may be used.
- the inorganic salts of bismuth, antimony and arsenic above named may be replaced by other salts having relatively non-toxic anions and capable of entering into double decomposition with cevitamates; i! desired, the hydroxides of the metals may be used, but they generally react with cevitamic acid only with difllculty.
- the sodium sulphite may be used with or be substituted by the soluble salts 01 other weak acids, like these citrates, or by sucrose, organic acids like tartaric and citric acids, or other stabilizers which are suitable for injection.
- the cevitamates may be employed in the form of isotonic solutions, which may be prepared by the addition of a suitable quantity of sodium chloride or other salt thereto.
- the method oi preparing a therapeutically valuable compound of bismuth which comprises dissolving cevitamic acid in a suitable solvent, adding thereto a soluble bismuth salt, whereby a reaction takes place to form the metal compound of said acid, and isolating the reaction product.
- the method of preparing a new bismuth compound having therapeutic properties which comprises dissolving cevitamic acid in a suitable solvent, and adding thereto an alkali and a compound of bismuth capable of reacting with cevitamic acid, whereby a reaction takes place to form the bismuth compound of cevitamic acid.
- a therapeutic preparation comprising the solubilized reaction product of cevitamic acid and a compound of bismuth capable of reacting therewith.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Patented Oct. 21, 1941 THERAPEUTIC PREPARATION OF BISMUTH AND METHOD OF PREPARING SAME Simon L. Ruskin, New York, NY.
No Drawing. Application May 28, 1938, Serial No. 210,772
Claims. The present invention relates to therapeutic preparations for the administration of bismuth, antimony and arsenic into the human organism.
The present application is a continuation-inpart of my copending application Serial No.
745,527, filed September 26, 1934.
A number of organic compounds of bismuth,
antimony and arsenic are now in use for the treatment of various diseases, such as syphilis and trypanosomiasis, but their application is frequently attended by irritation and even poisoning, and sometimes gives rise to dermatitis, gingivitis and other affections. While these detrimental side eifects are generally due to the susceptibility oi the patient to bismuth, antimony and arsenic poisoning, they are frequently due,
at least in part, and sometimes perhaps evenentirely, to the other constituents of the medicinal compound. It is my belief that the untoward eifects, or a great part of them, obtained with the use of known compounds of the abovenamed metals can to a great extent be traced to the fact that the remainder of the, molecule is just as foreign to the human organism, and particularly to the blood stream, as the metal it is sought to introduce, and just as poisonous or diflicultly tolerable, so that the system receives a double shock from both the therapeutic metal and the organic radical to which it is Joined.
It is accordingly the general object of the invention to provide new preparations of bismuth, antimony and arsenic, constituting group Vb oi. the periodic system, having spirochaetocidal and trypanosomicidal activity and characterized by being considerably .less toxic than the known preparations containing these metals and currently used in the treatment of syphilis, trypanosomiasis and kindred diseases.
It is a further object oi. the invention to provide therapeutic preparations of bismuth, antimony and arsenic which can be more readily tolerated by the human organism and possess the unique property of inhibiting the tendency to dermatitis and gingivitis commonly observed during bismuth, antimony and arsenic therapy. Other objects and advantages of the invention will appear from the more detailed description hereinbelow.
In accordance with the present invention, the bismuth, antimony and arsenic are administered in the form of the cevitamate or laevo-ascorbate in dosages common for these metals. I have found that the cevitamic acid radical oiiers an unusually effective and non-toxic vehicle for the introduction of these otherwise poisonous metals or metalloids into the human organism. The peculiar structure 01' cevitamic acid, which supplies both oxidation and reduction mechanisms. makes it a remarkable detoxicating agent and the bismuth, antimony and arsenic cevitamates are thus less toxic and more easily tolerated by the body than known preparations of bismuth, antimony and arsenic. It is currently believed that antiluetic preparations are rendered more active when subjected to the oxidizing and reducing substances of the body. I have found that the cevitamate radical exerts this action when combined with bismuth, antimony and arsenic and thus increases the activity of the metal while at the same time reducing its toxic effects.
I have found further that the cevitamic acid compound of the above named metals are quite soluble in water and with the aid of a stabilizing agent, and particularly at a pH value of about 7.6 or slightly higher, can be kept indefinitely in solution. Moreover, these salts possess also the physiological action of cevitamic acid, and thus simultaneously act to correct morbid conditions arising from a deficiency of vitamin C.
My invention willbe further described with the aid of the following examples which are presented purely by way of illustration and not as indicating the scope of the invention:
EXAMPLE l.Preparation of bismuth cem'tamate 1.8 cevitamic acid (about .01 mol) were dissolved in 20 cc. glycerol and 10 cc. N NaOH. To this were then added under stirring and cooling 35 cc. N NaOH and 22.5 cc. Bi(NO3)35H2O (containing mol) in the following order:
NaOH Bi(NOa)351-I2O (1) 5 cc.. (2) 2.5 cc. (3) 5 cc (4) 2.5 cc. (5) 5 cc (6) 2.5 cc. (7) 5 cc (8) 2.5 cc. (9) 5 oc (10) 2.5 cc.
(11) 5 cc (12) 2.5 cc. (13) 5 cc (14) 7.5 cc.
saturated saline (NaCl) solution.
aiiltercellandtotheilltrate25caliu50asolution (containing 250 mg.) were now'added to stabilize it and it was brought down to a pH around 7.6 with excess cevitamic acid. It was then made up to 150 cc. with distilled water and bottled immediately. The preparation should contain approximately 20 mg. Bi per cc.
Exmru: 2. Preparatin of antimony cevitamate 1.8 g. cevitamic acid were dissolved in 10 cc. To this was added slowly under stirring 4.3 g. SbCl: dissolved in 20 cc. saturated saline solution. The acid solution was cooled with ice, and under stirring and cooling 12 cc. N NaOH saturated with salt were added. This left the solution still acid. The precipitate was centrifuged, and was then washed three times by centriiugation with distilled water. The moist precipitate weighing 4.8 g. when dry (theory 4.9 g.) was now suspended in 100 cc. of 50% glycerol solution and 5N alkali solution was dropped in under violent stirring until a faint permanent cloudiness remained. The solution was filtered through a filter cell until clear. It
should have a pH around 9.6. There were then added 2.5. cc. NarSOa (containing 250 mg.) to stabilize the'solution. If a lower pH is desired a little excess cevitamic acid could be added. The solution was then made up to 150 cc. and bottled immediately. This solution should contain approximately 16 mg. Sb per cc.
The reaction may be represented as follows:
CHQOSMOH): CHsOBMOH):
HOSb(0H)s HOBMOH):
H HOE NaOH 4: OH OH Sb calc. 50.02% l p-211 I OH Sb i'ound 49.82% J COONa Exsmmn 3.Preparation of arsenic cevitamate 20 g. (100 cc.) arsenious chloride were dissolved in 50 'cc. absolute alcohol and the solution shaken up with 1.8 g. cevltamic acid. Practically all the acid went into solution which would not have been the case if the arsenius chloride had been absent. This indicated the formation of arsenic cevitamate. The arsenic cevitamate is less toxic than currently used arsenic preparations in the treatment of syphilis. The pH may be adjusted with sodium hydroxide or other alkali.
. The solutions of the cevitamates above described may be packaged in ampoules or ii desired m the solid condition in the form of tablets.
e compounds may be prepared in an indifierent atmosphere, like ,Nz or CO2, but this is not absolutely necessary; while if desired the ampoules may be charged in such an atmosphere or may have C02 dissolved in the solution.
Various organic acids can be employed for adjusting the pH to a lower alkalinity, care being taken to avoid precipitation. Tartaric, citric, gluconic and other 'injectible organic acids may be used for this purpose. To bring the pH down from above 9 to 8, tartaric or citric acid is satisfactory, whereas gluconic acid may cause precipitation.
Local anaesthetics such as chlorbutanol or benzyl alcohol may be added to reduce tissue sensitivity. They likewise have a desirable eiiect on the stability of the solution.
The bismuth, antimony and arsenic cevitamates are administered parenterally, preferably intramuscularly. The dosage may amount to 20 to 40 mg. of the metal once or twice weekly. They are all suitable for the treatment 01! syphilis and protozoan diseases, like trypanosomiasis.
In syphilis. various known arsenic and bismuth preparations will not influence the Wassermann reaction in some cases. These "Wassermann iast" cases responded better to bismuth cevitamate than to known bismuth and arsenic preparations.
In place of NaOH, other bases may be employed, such as KOH, NazCOa, etc., while in place of cevltamic acid and a base, a salt of cevitamic may be used. The inorganic salts of bismuth, antimony and arsenic above named may be replaced by other salts having relatively non-toxic anions and capable of entering into double decomposition with cevitamates; i! desired, the hydroxides of the metals may be used, but they generally react with cevitamic acid only with difllculty. The sodium sulphite may be used with or be substituted by the soluble salts 01 other weak acids, like these citrates, or by sucrose, organic acids like tartaric and citric acids, or other stabilizers which are suitable for injection. The cevitamates may be employed in the form of isotonic solutions, which may be prepared by the addition of a suitable quantity of sodium chloride or other salt thereto.
Variations from the specific methods of procedure above described will occur to those skilled in the art without departing from the spirit oi the invention.
I claim:
1. The method oi preparing a therapeutically valuable compound of bismuth, which comprises dissolving cevitamic acid in a suitable solvent, adding thereto a soluble bismuth salt, whereby a reaction takes place to form the metal compound of said acid, and isolating the reaction product.
2. The method of preparing a therapeutically valuable compound of bismuth, which comprises dissolving cevitamic acid in a suitable solvent,
adding thereto a base and a soluble bismuth salt, whereby a reaction takes place to form the bismuth compound of saldacid, and isolating the reaction product.
3. The method of preparing a new bismuth compound having therapeutic properties which comprises dissolving cevitamic acid in a suitable solvent, and adding thereto an alkali and a compound of bismuth capable of reacting with cevitamic acid, whereby a reaction takes place to form the bismuth compound of cevitamic acid.
4. The cevitamic acid compound of bismuth.
5. A therapeutic preparation comprising the solubilized reaction product of cevitamic acid and a compound of bismuth capable of reacting therewith.
SIMON L. RUSKIN.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US210772A US2259492A (en) | 1938-05-28 | 1938-05-28 | Therapeutic preparation of bismuth and method of preparing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US210772A US2259492A (en) | 1938-05-28 | 1938-05-28 | Therapeutic preparation of bismuth and method of preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2259492A true US2259492A (en) | 1941-10-21 |
Family
ID=22784204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US210772A Expired - Lifetime US2259492A (en) | 1938-05-28 | 1938-05-28 | Therapeutic preparation of bismuth and method of preparing same |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2259492A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2415555A (en) * | 1942-09-25 | 1947-02-11 | Ernst A H Friedheim | Organometallic compounds containing 1, 3, 5-triazine rings |
| US2418115A (en) * | 1943-10-16 | 1947-04-01 | Ernst A H Friedheim | Organometallic compounds containing 1, 3, 5-triazine rings |
| US2684323A (en) * | 1950-10-21 | 1954-07-20 | Physiological Chemicals Compan | Procaine ascorbate preparation |
| US6294678B1 (en) | 1997-01-14 | 2001-09-25 | George P. Sakalosky | Treatment for cancer and compounds for use therewith |
| US6565895B2 (en) | 2000-06-08 | 2003-05-20 | Geltex Pharmaceuticals, Inc. | Bismuth compounds for the treatment and prevention of mucositis |
| US20030181436A1 (en) * | 2001-11-13 | 2003-09-25 | Sakalosky George P. | Treatment for AIDS, HIV, and other related diseases and compounds for use therewith |
-
1938
- 1938-05-28 US US210772A patent/US2259492A/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2415555A (en) * | 1942-09-25 | 1947-02-11 | Ernst A H Friedheim | Organometallic compounds containing 1, 3, 5-triazine rings |
| US2418115A (en) * | 1943-10-16 | 1947-04-01 | Ernst A H Friedheim | Organometallic compounds containing 1, 3, 5-triazine rings |
| US2684323A (en) * | 1950-10-21 | 1954-07-20 | Physiological Chemicals Compan | Procaine ascorbate preparation |
| US6294678B1 (en) | 1997-01-14 | 2001-09-25 | George P. Sakalosky | Treatment for cancer and compounds for use therewith |
| US6565895B2 (en) | 2000-06-08 | 2003-05-20 | Geltex Pharmaceuticals, Inc. | Bismuth compounds for the treatment and prevention of mucositis |
| US20030181436A1 (en) * | 2001-11-13 | 2003-09-25 | Sakalosky George P. | Treatment for AIDS, HIV, and other related diseases and compounds for use therewith |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2259492A (en) | Therapeutic preparation of bismuth and method of preparing same | |
| US3830824A (en) | Physiological organic acid silver allantoinates | |
| US2250553A (en) | Medicinal preparation | |
| JPS63201187A (en) | 4-thiazolidinecarboxylic acid derivative, manufacture and medicine composition | |
| US4185093A (en) | Preparation and method for treatment of hypocalcemia, hypophosphatemia and downer cow syndrome in animals | |
| DE2947624A1 (en) | BETA, GAMMA -DIHYDROPOLYPRENYL ALCOHOL AND HEM-PRESSURING MEDICINE CONTAINING THEM | |
| US2081547A (en) | Therapeutic agent | |
| DE3686514T2 (en) | N- (2-CARBOXY) -ETHYL-1,8-NAPHTHALENIMIDE AND ITS SALTS FOR THE TREATMENT OF DIABETIC RETINOPATHIES AND NEUROPATHIES. | |
| US2135474A (en) | Radiographic substance | |
| US3306819A (en) | Derivative of pectin, its process of preparation and its method of use | |
| US2312195A (en) | Salts of dextro-ascorbic acid and method of preparing same | |
| DE3212817C2 (en) | ||
| US3920824A (en) | Stable ophthalmic formulation | |
| US2395069A (en) | Preparations of arsenic and antimony | |
| US2939817A (en) | Method of treating diseases associated with plasmin activity | |
| DE1806926A1 (en) | Lithium salt of hydroquinone sulfonic acid | |
| JPS62294616A (en) | Fungicidal drug, manufacture and therapy | |
| US2669563A (en) | Bismuth salt of penicillin | |
| US2941924A (en) | Monoethanolamine salt of alpha-(acetylamino)-isocaproic acid | |
| US2100054A (en) | Anesthetic tannate | |
| US3071508A (en) | Compositions for oral administration in unit dosage form for prophylaxis and treatment of poison ivy and poison sumac dermatitis | |
| US2608508A (en) | N-amylsulfamyl benzoic acids | |
| DE69328357T2 (en) | COMPLEX OF 2-AMINOETHANESULPHONIC ACID AND ZINC | |
| DE2408372C3 (en) | Therapeutically acceptable salts of p-chlorohippuric acid and pharmaceutical preparations containing these or p-chlorohippuric acid | |
| Barrie et al. | Calcium disodium edathamil in the treatment of ferrous sulfate poisoning |